Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
- NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020
- Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers
- Regulatory filing for rimegepant in Europe submitted and accepted for review by European Medicines Agency for dual-acting (acute and prevention) indication for treatment of migraine
- Life-cycle management studies for CGRP-antagonist program underway, including initiation of Phase 4 study of NURTEC ODT in pediatric migraine
China
Japan
United-states
Israel
Kuwait
Massachusetts
Science-park
South-africa
New-haven
Connecticut
United-arab-emirates
Yale-university